The association of glycogen synthase kinase-3beta (GSK-3β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients

International Journal of Bipolar Disorders

Volumn 1, Issue 1, 2013, Pages 1-5

  Rybakowski, Janusz K ^a   Abramowicz, Maria ^a   Szczepankiewicz, Aleksandra ^a   Michalak, Michal ^a   Hauser, Joanna ^a   Czekalski, Stanislaw ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

50 C T polymorphism; Glycogen synthase kinase 3beta; Kidney function; Lithium; Urine concentrating ability

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; GENOTYPING TECHNIQUE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VERY ELDERLY;

EID: 84930399865     PISSN: None     EISSN: 21947511     Source Type: Journal    
DOI: 10.1186/2194-7511-1-8     Document Type: Article

References (23)

1. Adiyanti SS, Loho T. Acute kidney injury (AKI) biomarker. Acta Med Indones. 2012; 44:246-255.
2. Adli M, Hollinde DL, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, Heinz A, Bauer M. Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta -50T/C single nucleotide polymorphism. Biol Psychiatry. 2007; 62:1295-1302.
3. Benedetti F, Serretti A, Pontiggia A, Bernasconi A, Lorenzi C, Colombo C, Smeraldi E. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta -50 T/C SNP. Neurosci Lett. 2005; 376:51-55.
4. Benedetti F, Bolettini I, Barberi I, Radaelli D, Poletti S, Locatelli C, Pirovano A, Lorenzi C, Falini A, Colombo C, Smeraldi E. Lithium and GSK3-β promoter gene variants influence white matter microstructure in bipolar disorder. Neuropsychopharmacology. 2013; 38:313-327.
5. Bradley CA, Peineau S, Taghibiglou C, Nicolas CS, Whitcomb DJ, Bortolotto ZA, Kaang BK, Cho K, Wang YT, Collingridge GL. A pivotal role of GSK-3 in synaptic plasticity. Front Mol Neurosci. 2012; 5:13.
6. Dugo L, Collin M, Allen DA, Patel NS, Bauer I, Mervaala EM, Louhelainen M, Foster SJ, Yagoob MM, Thiemermann C. GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med. 2005; 33:1903-1912.
7. First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press; 1996.
8. Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology. 2005; 30:1223-1237.
9. Grünfeld JP, Rossier BC. Lithium neurotoxicity revisited. Nat Rev Nephrol. 2009; 5:270-276.
10. Hartigan G. The use of lithium salts in affective disorders. Br J Psychiatry. 1963; 109:810-814.
11. Iitaka C, Miyazaki K, Akaike T, Ishida N. A role for glycogen synthase kinase-3 beta in the mammalian circadian lock. J Biol Chem. 2005; 280:29397-29402.
12. Kokot F, Hyla-Klekot L, Kokot S. Badania laboratoryjne. Zakres norm i interpretacja. (in Polish). Warszawa: Wydawnictwo Lekarskie PZWL; 2011: p. 9-375.
13. Kwok JB, Hallupp M, Loy CT, Chan DK, Woo J, Mellick GD, Buchanan DD, Silburn PA, Halliday GM, Schofield PR. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol. 2005; 58:829-839.
14. Lin YF, Huang MC, Liu HC. Glycogen synthase kinase 3β gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium. J Affect Disord. 2013; 147:401-406.
15. Lisowska-Myjak B. Serum and urinary biomarkers of kidney injury. Blood Purif. 2010; 29:357-365.
16. Miller SA. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16:1215.
17. Presne C, Fakhouri F, Noel LH, Stengel B, Even C, Kreis H, Mignon F, Grünfeld JP. Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int. 2003; 64:585-592.
18. Rao R. Glycogen synthase kinase-3 regulation of urinary concentrating ability. Curr Opin Nephrol Hypertens. 2012; 21:541-546.
19. Russ C. Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease. Mol Psychiatry. 2001; 6:320-324.
20. Rybakowski JK. Lithium in neuropsychiatry: a 2010 update. World J Biol Psychiatry. 2011; 12:340-348.
21. Schou M, Vestergaard P. Prospective studies on a lithium cohort. 2. Renal function. Water and electrolyte metabolism. Acta Psychiatr Scand. 1988; 78:427-433.
22. Stambolic V, Ruel L, Woogdett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signaling in intact cells. Curr Biol. 1996; 6:1664-1668.
23. Szczepankiewicz A, Rybakowski JK, Suwalska A, Skibinska M, Leszczynska-Rodziewicz A, Dmitrzak-Weglarz M, Czerski PM, Hauser J. Association study of the glycogen synthase kinase-3βgene polymorphism with prophylactic lithium response in bipolar patients. World J Biol Psychiatry. 2006; 7:158-161.